

**Michael J. Goodheart, MD**

**Articles:**

Devor EJ, Goodheart MJ, Leslie KK. Towards a microRNA signature of endometrial cancer. *Proc Obstet Gynecol.* 2011 July;2(1):Article[7 p]. Available from: <http://ir.uiowa.edu/pog/>. Free full text article.

Girardi J, Goodheart MJ. Diagnosis of endometrial cancer complicated by morbid obesity—a case report. *Proc Obstet Gynecol.* 2011 July;2(1):Article 15 [5 p]. Available from: <http://ir.uiowa.edu/pog/>. Free full text article.

Shelton, DN, Goodheart MJ. Wnt/ $\beta$ -catenin/Lef-1 signaling in the uterus and its implications in uterine gland formation and cancer development. *Proc Obstet Gynecol.* 2011 July;2(1):Article 16 [11 p.]. Available from: <http://ir.uiowa.edu/pog/>. Free full text article.

Xie W, Fisher JT, Lynch TJ, Luo M, Evans TI, Neff TL, Zhou W, Zhang Y, Ou Y, Bunnett NW, Russo AF, Goodheart MJ, Parekh KR, Liu X, Engelhardt JF. CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice. *J Clin Invest.* 2011 Aug;121(8):3144-58. Epub 2011 Jul 18. PubMed PMID: 21765217; PubMed Central PMCID: PMC3148720. doi: 10.1172/JCI41857

Shamshirsaz AA, Buekers T, Degeest K, Bender D, Zamba G, Goodheart MJ. A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival. *Int J Gynecol Cancer.* 2011 Oct;21(7):1232-40. PubMed PMID: 21720254. DOI: 10.1097/IGC.0b013e318220fc46

Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S, Leslie KK. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. *Oncol Rep.* 2011 Oct;26(4):995-1002. doi: 10.3892/or.2011.1372. Epub 2011 Jul 1. PubMed PMID: 21725615. <http://dx.doi.org/10.3892/or.2011.1372>

Clevenger L, Schrepf A, Christensen D, Degeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. *Brain Behav Immun.* 2012 Apr 21. [Epub ahead of print] PubMed PMID: 22543257. <http://dx.doi.org/10.1016/j.bbi.2012.04.003>

Engle DB, Connor JP, Morris PC, Bender DP, De Geest K, Ahmed A, Goodheart MJ. Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. *Arch Gynecol Obstet.* 2012 May 9. [Epub ahead of print] PubMed PMID: 22569711. <http://dx.doi.org/10.1007/s00404-012-2351-1>

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S. Endometrial cancer. *Obstet Gynecol Clin North Am.* 2012 Jun;39(2):255-68. PubMed PMID: 22640714. <http://dx.doi.org/10.1016/j.ogc.2012.04.001>

Shelton DN, Fornalik H, Neff T, Park SY, Bender D, Degeest K, Liu X, Xie W, Meyerholz DK, Engelhardt JF, Goodheart MJ. The Role of LEF1 in Endometrial Gland Formation and Carcinogenesis. *PLoS One.* 2012;7(7):e40312. Epub 2012 Jul 6. PubMed PMID: 22792274; PubMed Central PMCID: PMC3391280. <http://dx.doi.org/10.1371/journal.pone.0040312>

Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmouh L, Zimmerman MB, Penedo FJ, Lucci JA 3rd, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AK. Social Influences on Clinical Outcomes of Patients With Ovarian Cancer. *J Clin Oncol.* 2012 Jul 16. [Epub ahead of print] PubMed PMID: 22802321. <http://dx.doi.org/10.1200/JCO.2011.39.4411>

Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. *Curr Oncol Rep.* 2012 Aug;14(4):277-84. PubMed PMID: 22532266. <http://dx.doi.org/10.1007/s11912-012-0238-8>

#### **Abstracts:**

Engle D, Fornalik H, Neff T, Button A, Collins K, Ahmed A, DeGeest K, Bender D, Lutgendorf S, Goodheart M. Comparison of p53 mutation status, primary cytoreductive surgical outcomes, and overall survival in patients with ovarian cancer. Western Association of Gynecologic Oncologist Meeting, Park City, Utah, June 16-18, 2011.

Girardi J, Samuelson M, Button A, DeGeest K, Bender D, Ahmed A, Goodheart M. The relationship between vascularity, p53 gene mutations and distant metastatic disease in epithelial ovarian carcinoma. Western Association of Gynecologic Oncologist Meeting, Park City, Utah, June 16-18, 2011.

Clements A, Engle D, Shelton D, Neff T, Park S, Bender D, Ahmed A, DeGeest K, Button A, Engelhardt J, Goodheart M. Lymphoid Enhancing Factor-1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancer and associations with clinical factors. Western Association of Gynecologic Oncologist Meeting, Park City, Utah, June 16-18, 2011.

Nadkarni N, Rogers L, Samuelson M, Neff T, Bender D, Ahmed A, DeGeest K, Button A, Dupuy A, Goodheart M. Zmiz1 is overexpressed in epithelial ovarian cancer and is associated with p53 gene mutations. Western Association of Gynecologic Oncologist Meeting, Park City, Utah, June 16-18, 2011.

Rosenbluth, EM, Shelton DN, Neff TN, Van Voorhis BJ, Goodheart MJ. Lymphoid Enhancing Factor-1 (Lef-1) is over expressed in benign endometria as

body mass index increases. American Society for Reproductive Medicine. Orlando, FL, October 15-19, 2011.

Nadkarni N, Rogers L, Samuelson M, Neff T, Bender D, Ahmed A, DeGeest K, Button A, Dupuy A, Goodheart MJ. ZMIZ1 is elevated in epithelial ovarian cancer due to an upregulated alternative promoter and is associated with p53 mutations. American Association for Cancer Research. Chicago, IL, March 31-April 4, 2012.